Company profile
TG THERAPEUTICS, INC.
NASDAQ:TGTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BRIUMVI | approved | — | 0 | — |
| UKONIQ | approved | — | 0 | — |
| UMBRALISIB | phase3 | — | 17 | completed, terminated |
| COSIBELIMAB | phase1 | — | 2 | completed, terminated |
| EDRALBRUTINIB | phase1 | — | 1 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (36)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06680037 | phase1 | recruiting | 2025-05-06 | 2026-12-01 | TG Therapeutics, Inc. | A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders |
| NCT07503873 | phase2 | recruiting | 2026-04-01 | 2027-07-31 | TG Therapeutics, Inc. | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) |
| NCT07673744 | phase2 | recruiting | 2026-10-01 | 2028-07-01 | TG Therapeutics, Inc. | A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG) |
| NCT07211633 | phase3 | active_not_recruiting | 2025-07-09 | 2026-10-31 | TG Therapeutics, Inc. | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) |
| NCT02656303 | phase2 | terminated | 2016-01-07 | 2022-05-26 | TG Therapeutics, Inc. | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761238 | 2022-12-28 | BLA | TG THERAPEUTICS, INC. | |||||
Loading… | ||||||||
| NDA 213176 | 2021-02-05 | NDA | TG THERAPEUTICS INC | |||||
Loading… | ||||||||